More Weekly Activity Was Tied to Slower Parkinson’s Decline
A higher weekly activity load was linked to slower progression of Parkinson’s disease across both cognitive and movement-related outcomes in a longitudinal cohort of 294 adults with mild-to-moderate disease. Participants who reported more than 8 hours of physical activity per week fared best over time, with slower decline in cognition over 5 years and improvement in motor symptoms over 7 years.
The finding fits with a long-standing clinical intuition: movement may do more than preserve mobility in Parkinson’s disease. It may also preserve neural function long enough to delay the downward slope that often becomes visible in clinic visits year after year.
How the Cohort Was Followed Over Time
The cohort came from the Cincinnati Cohort Biomarker Program, a prospective study of adults with Parkinson’s disease. Average age was 66, and around one third of participants were female. Annual assessments tracked motor symptoms for up to 7 years and cognition for up to 5 years, although not every participant contributed data at every visit. The median follow-up duration was 3 years for both analyses.
Physical activity was self-reported and captured in three ways: total weekly time spent active, total weekly vigorous exercise, and total weekly volume of activity with greater weight given to vigorous exercise. The categories were straightforward. Low activity meant up to 4 hours per week, medium activity meant 4 to 8 hours, and high activity meant more than 8 hours.
The framing matters because Parkinson’s progression is not a single axis. Motor impairment and cognitive change can move at different speeds, and a therapy or lifestyle factor that affects one domain may not touch the other. Here, both moved in the same direction.
Motor Scores Moved in the Favorable Direction
Motor severity was measured with a scoring system ranging from 0 to 132, where higher scores indicate worse symptoms. Participants entered the study with an average score of 23. Over time, the low-activity group showed an estimated annual increase of 0.143 points. The medium-activity group showed an estimated annual decrease of 0.225, while the high-activity group showed an estimated annual decrease of 0.783.
Those are modest annual differences, but Parkinson’s disease is cumulative. A small annual gap can widen when it is sustained across several years, especially when baseline function is still relatively preserved.
In practical terms, the motor data suggest that staying physically active may help slow the steady accumulation of disability that follows gait disturbance, rigidity, and bradykinesia. Exercise may support dopamine-dependent circuits, improve gait mechanics, and preserve reserve in systems that are already under chronic stress from neurodegeneration.
Cognitive Decline Was Also Slower in the Most Active Group
Cognition was assessed with a scale ranging from 0 to 30, where lower scores indicate worse function. In this analysis, the low-activity group had an estimated annual decrease of 0.478 points. The medium-activity group declined by 0.090 points annually, and the high-activity group by 0.007 points.
The cognitive result is especially important because cognitive symptoms in Parkinson’s disease are often harder to manage with medication alone than motor symptoms. Clinicians routinely use drug therapy, behavioral support, and counseling strategies for cognitive concerns, but the biological options remain limited once decline begins. An association between higher activity and slower cognitive deterioration raises the possibility that exercise is acting upstream, before impairment becomes more entrenched.
There is a plausible mechanistic explanation. Physical activity can improve vascular health, regulate inflammation, and support neuroplasticity in brain networks that are vulnerable in Parkinson’s disease. Those effects would not be expected to cure the disorder, but they could slow the pace at which functional systems unravel.
Total Activity Mattered More Than Vigorous Exercise Alone
One of the more clinically useful findings was that vigorous exercise by itself was not associated with long-term outcomes after adjustment for total activity. In other words, overall weekly activity appeared to matter more than whether those minutes were especially intense.
That is an important bedside message. A rigid message that only strenuous exercise counts can discourage patients who are already struggling with fatigue, stiffness, or balance concerns. The data point in a different direction: consistency and total volume may be the more relevant targets, not intensity alone.
This also aligns with how Parkinson’s disease behaves in daily life. Activity is not just gym time. It includes work, household movement, walking, hobbies, and the accumulation of routine physical effort that keeps a person engaged in the world rather than sedentary at home.
Why the Association Cannot Be Treated as Proof
The study remains observational, and that limits how far the results can be pushed. Self-reported activity is vulnerable to error, and people with better preserved cognition and milder disease may simply be more able to stay active in the first place. Reverse causation is a real concern in this kind of research.
Participants also started with generally good cognitive function, which narrows the room for detecting large differences over time. The follow-up data were incomplete at some visits, and the cognitive and motor analyses did not always include the same participants across the same duration.
These limitations do not erase the signal. They do mean the signal should be read as association rather than disease modification. In a progressive neurodegenerative disorder, that distinction remains central.
What Clinicians Can Do With This Now
The most actionable message is simple: encourage movement early, and encourage it consistently. Exercise is already part of standard nonpharmacologic Parkinson’s care for motor symptoms, and this cohort suggests the benefit may extend into cognition as well.
Derk W. Krieger, a neurologist who was not involved in the study, described the findings as encouraging but cautioned that patients with milder disease and better cognition may simply be more active. Dong-Woo Ryu, the study author, pointed to the need for larger cohorts, longer follow-up, imaging, biological biomarkers, and digital tools that can measure activity more accurately.
Daniel Truong, also not involved in the research, framed exercise as one of the most important nonpharmacological strategies in Parkinson’s disease and advised starting small, choosing something enjoyable, and making the activity social. That advice fits the study well. The threshold signal was not built on elite training; it was built on sustained weekly movement.
The next question is not whether exercise belongs in Parkinson’s care. It already does. The unresolved issue is how much of the observed benefit reflects direct neurobiologic protection, and how much reflects the fact that patients who remain active are also those whose disease is moving more slowly in the first place.